Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis
Psoriasis patients are known to be at increased risk for heart disease. This may be due to the increased prevalence of cardiovascular disease risk factors in this population, including high blood pressure, diabetes, obesity, and high cholesterol. Although cholesterol levels are known to be altered in psoriasis, most studies have used standard lipid profiles to measure cholesterol. These tests indirectly measure LDL (bad cholesterol) and become less accurate when triglyceride levels are high, as often see in individuals with psoriasis. We have designed a case-control study that uses a more specific and detailed cholesterol test to measure serum lipid levels in psoriasis patients, allowing for more accurate determination of LDL and better assessment of the lipid-contribution to cardiovascular risk. We will also measure other markers of inflammation that may contribute to cardiovascular disease.
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||A Case Control Study to Evaluate Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis.|
- Evaluate differences in serum lipid levels in psoriasis patients compared to controls through the use of a relatively new comprehensive lipid profile test that has not been used in previous psoriasis studies. [ Time Frame: After consent is obtained ] [ Designated as safety issue: No ]
- Compare other cardiovascular biomarkers such as high-sensitivity C-Reactive Protein in psoriasis patients verses controls. [ Time Frame: After consent is obtained. ] [ Designated as safety issue: No ]
- Identify if an association exists between the extent and severity of psoriasis and measured lipid levels [ Time Frame: After consent is obtained ] [ Designated as safety issue: No ]
|Study Start Date:||November 2009|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Individuals with a diagnosis of psoriasis as confirmed by the principle investigator will comprise the psoriasis or case group. Participants must meet inclusion and exclusion criteria as defined below. This group will consist of 100 individuals.
Individuals without psoriasis, but meeting inclusion and exclusion criteria, will be selected to be within the control group. For each patient with psoriasis within the psoriasis group, an age, sex, and BMI-matched control will be selected. The group will consist of 100 individuals.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01019200
|Contact: Monica Rengifo-Pardoemail@example.com|
|United States, District of Columbia|
|The George Washington University Dermatology Clinic||Recruiting|
|Washington, District of Columbia, United States, 20037|
|Contact: Alison Ehrlich, MD 202-741-2600|
|Principal Investigator: Alison Ehrlich, MD|
|Sub-Investigator: Lisa W Martin, MD|
|Sub-Investigator: Amir Zahir, MD|
|Principal Investigator:||Alison Ehrlich, MD||GWU|
|Study Chair:||Lisa W Martin, MD||GWU|
|Study Chair:||Monica Rengifo-Pardo||GWU|